Literature DB >> 28103134

The role of nuclear factor of activated T cells in pulmonary arterial hypertension.

Rui Chen1, Jinchuan Yan1, Peijing Liu1, Zhongqun Wang1, Cuiping Wang1, Wei Zhong1, Liangjie Xu1.   

Abstract

Nuclear factor of activated T cells (NFAT) was first identified as a transcription factor about 3 decades ago and was not well studied until the development of immunosuppressant. Numerous studies confirm that calcineurin/NFAT signaling is very important in the development of vasculature and cardiovascular system during embryogenesis and is involved in the development of vascular diseases such as hypertension, atherosclerosis and restenosis. Recent studies demonstrated that NFAT proteins also regulate immune response and vascular cells in the pulmonary microenvironment. In this review, we will discuss how different NFAT isoforms contribute to pulmonary vascular remodeling and potential new therapeutic targets for treating pulmonary arterial hypertension.

Entities:  

Keywords:  NFAT; calcineurin; hypoxia; proliferation; pulmonary arterial hypertension; vascular remodeling

Mesh:

Substances:

Year:  2017        PMID: 28103134      PMCID: PMC5384583          DOI: 10.1080/15384101.2017.1281485

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  67 in total

1.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

Authors:  Robyn J Barst; David Langleben; David Badesch; Adaani Frost; E Clinton Lawrence; Shelley Shapiro; Robert Naeije; Nazzareno Galie
Journal:  J Am Coll Cardiol       Date:  2006-04-24       Impact factor: 24.094

Review 2.  Nuclear factor of activated T-cells transcription factors in the vasculature: the good guys or the bad guys?

Authors:  Lisa M Nilsson; Jenny Nilsson-Ohman; Anna V Zetterqvist; Maria F Gomez
Journal:  Curr Opin Lipidol       Date:  2008-10       Impact factor: 4.776

3.  Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.

Authors:  D J Williamson; L L Wallman; R Jones; A M Keogh; F Scroope; R Penny; C Weber; P S Macdonald
Journal:  Circulation       Date:  2000-07-25       Impact factor: 29.690

4.  Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension.

Authors:  Gopinath Sutendra; Sebastien Bonnet; Gael Rochefort; Alois Haromy; Karalyn D Folmes; Gary D Lopaschuk; Jason R B Dyck; Evangelos D Michelakis
Journal:  Sci Transl Med       Date:  2010-08-11       Impact factor: 17.956

5.  Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects.

Authors:  Yasuaki Kishimoto; Taichi Kato; Mikako Ito; Yoshiteru Azuma; Yoshie Fukasawa; Kinji Ohno; Seiji Kojima
Journal:  J Thorac Cardiovasc Surg       Date:  2015-05-22       Impact factor: 5.209

6.  Activation of the Ca(2+)/calcineurin/NFAT2 pathway controls smooth muscle cell differentiation.

Authors:  Daniel Larrieu; Pierre Thiébaud; Cécile Duplàa; Igor Sibon; Nadine Thézé; Jean-Marie Daniel Lamazière
Journal:  Exp Cell Res       Date:  2005-10-15       Impact factor: 3.905

7.  Endothelin-1-dependent nuclear factor of activated T lymphocyte signaling associates with transcriptional coactivator p300 in the activation of the B cell leukemia-2 promoter in cardiac myocytes.

Authors:  Teruhisa Kawamura; Koh Ono; Tatsuya Morimoto; Masaharu Akao; Eri Iwai-Kanai; Hiromichi Wada; Naoya Sowa; Toru Kita; Koji Hasegawa
Journal:  Circ Res       Date:  2004-04-29       Impact factor: 17.367

8.  NFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.

Authors:  Juan Manuel Ramiro-Diaz; Carlos H Nitta; Levi D Maston; Simon Codianni; Wieslawa Giermakowska; Thomas C Resta; Laura V Gonzalez Bosc
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-08       Impact factor: 5.464

9.  Preliminary in vivo pharmacokinetic and pharmacodynamic evaluation of a novel calcineurin-independent inhibitor of NFAT.

Authors:  Tudor Bîrsan; Camille Dambrin; Kennan C Marsh; Wolfgang Jacobsen; Stevan W Djuric; Karl W Mollison; Uwe Christians; George W Carter; Randall E Morris
Journal:  Transpl Int       Date:  2004-01-21       Impact factor: 3.782

10.  Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus.

Authors:  S Morelli; M Giordano; P De Marzio; R Priori; A Sgreccia; G Valesini
Journal:  Lupus       Date:  1993-12       Impact factor: 2.911

View more
  6 in total

1.  Systems Analysis of the Human Pulmonary Arterial Hypertension Lung Transcriptome.

Authors:  Robert S Stearman; Quan M Bui; Gil Speyer; Adam Handen; Amber R Cornelius; Brian B Graham; Seungchan Kim; Elizabeth A Mickler; Rubin M Tuder; Stephen Y Chan; Mark W Geraci
Journal:  Am J Respir Cell Mol Biol       Date:  2019-06       Impact factor: 6.914

2.  AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure.

Authors:  Anca Remes; Andreas H Wagner; Markus Hecker; Oliver J Müller; Nesrin Schmiedel; Markus Heckmann; Theresa Ruf; Lin Ding; Andreas Jungmann; Frauke Senger; Hugo A Katus; Nina D Ullrich; Norbert Frey
Journal:  Basic Res Cardiol       Date:  2021-06-04       Impact factor: 17.165

Review 3.  Role of NFAT in the Progression of Diabetic Atherosclerosis.

Authors:  Yaoyao Cai; Haipeng Yao; Zhen Sun; Ying Wang; Yunyun Zhao; Zhongqun Wang; Lihua Li
Journal:  Front Cardiovasc Med       Date:  2021-03-11

4.  Genome of Laudakia sacra Provides New Insights into High-Altitude Adaptation of Ectotherms.

Authors:  Chaochao Yan; Zhi-Yi Zhang; Yunyun Lv; Zeng Wang; Ke Jiang; Jia-Tang Li
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

5.  PDGF mediates pulmonary arterial smooth muscle cell proliferation and migration by regulating NFATc2.

Authors:  Fang-Yun Zhao; Shuang-Lan Xu; Chun-Fang Zhang; Jie Liu; Yue Zhang; Jiao Yang; Xi-Qian Xing
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

Review 6.  Hematopoietic Stem Cell Transcription Factors in Cardiovascular Pathology.

Authors:  Sushmitha Duddu; Rituparna Chakrabarti; Anuran Ghosh; Praphulla Chandra Shukla
Journal:  Front Genet       Date:  2020-10-16       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.